BPC-157 + TB-500 Blend Dosage and Protocols
BPC-157 + TB-500 Blend dosage protocols reported in published research, plus reconstitution and storage.
Dosage Protocols
Since BPC-157 is not FDA-approved for human use, there are no officially established dosing guidelines. The following information reflects dosages commonly reported in research literature and anecdotal use. Moderate dose: 250 to 500 mcg once or twice daily Higher dose: 500 to 800 mcg once or twice daily Weight-Based Dosing: Based on animal study extrapolations, an estimated human equivalent dose is approximately 1.6 mcg/kg body weight, translating to roughly 110 mcg for a 150-pound person and 145 mcg for a 200-pound person when using oral administration. Some users employ 4 weeks on, 2 to 4 weeks off protocols For acute injuries, shorter cycles of 2 to 4 weeks may be utilized Chronic conditions may warrant longer cycles under appropriate guidance
Subcutaneous Injection (Most Common)
Subcutaneous injection into the fatty tissue of the abdomen, thigh, or near the injury site is the most widely used method. The slower absorption profile of subcutaneous delivery suits BPC-157's mechanism: as a tissue-signaling peptide, it benefits from sustained presence in circulation rather than rapid spikes. Injecting close to the affected area is believed by some to provide more localized effects, though systemic distribution occurs regardless of injection site.
Intramuscular Injection
Some users prefer intramuscular injection, particularly when targeting specific muscle injuries. This method may provide more direct delivery to affected muscle tissue.
Oral Administration
Most peptides cannot survive oral delivery — the sequential barriers of stomach acid, intestinal enzymes, and first-pass liver metabolism degrade peptide bonds before they reach systemic circulation. BPC-157 is a rare exception. Originating from a protective protein in human gastric juice, it possesses intrinsic acid stability without requiring special formulation or absorption enhancers. This makes oral administration viable, particularly for gastrointestinal applications where the peptide can act locally on the gut lining. Oral capsules and sublingual formulations are available, though systemic bioavailability may differ from injectable forms — whether oral BPC-157 can reach distant injury sites at therapeutic concentrations remains an open question. For gut-focused protocols, see our best peptides for gut health guide .
Intra-articular Injection
For joint-related issues, some practitioners have utilized intra-articular injection. One retrospective study found that 7 of 12 patients with chronic knee pain reported symptom improvement lasting more than 6 months following a single intra-articular BPC-157 injection.
Results Timelines
Individual responses to BPC-157 vary considerably based on injury severity, administration method, dosage, and individual physiology. Based on available research and anecdotal reports: Initial reduction in inflammation and pain may be noticed Some users report improved mobility at injury sites Gastrointestinal benefits may become apparent for those using oral forms More noticeable improvements in tissue healing Enhanced range of motion and functional recovery Significant structural improvements in healing tissues Many users report substantial recovery milestones The peptide has a relatively short half-life of less than 30 minutes, following linear pharmacokinetics after administration. BPC-157 metabolites remain detectable in urine for up to 4 to 5 days.
Reported protocol doses
Doses shown are those reported in published research, not a recommendation.
References
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. · Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM · 2025
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. · Lee E, Padgett B · 2021
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM · 2025
- Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015. · Martinez JO, Evangelopoulos M, Bhavane R, Acciardo S, Salvatore F, Liu X, Ferrari M, Tasciotti E · 2015
- Thymosin β4 Promotes Dermal Healing. · Kleinman HK, Sosne G · 2016
- Gene ResultTMSB4X thymosin beta 4 X-linked [ (human)] - NCBI